Latest news with #Tarrytown
CBS News
a day ago
- Business
- CBS News
N.Y. company is using batteries to reduce stress on power grid. Here's how the Responsible Grid pilot program works.
A New York-based start-up company wants to use batteries to reduce stress on the energy grid and put money back in the pockets of state residents. The pilot program, courtesy of Standard Potential in Tarrytown, is called Responsible Grid. As the summer sun heats the streets and homes of New York City, it's no sweat for Addy Spiller and her dog to rest easy in their Upper West Side space. Spiller's is one of 65 households across the city participating in the pilot program, which kicked off this summer. "He was looking for beta testers and I said, 'Yes, please.' I love this kind of stuff," Spiller said. For her part, All Spiller had to was plug a battery into the wall and turn it on. From there she had power for her air conditioner, fan, Peloton, and home office. "When the grid is really strained, when everyone is using electricity during the summer heat waves, we can run the batteries and reduce the overall pressure on the grid," Standard Potential CEO Andrew Wang said. Wang says it's a simple system. "Don't need any permits and don't need any install. They don't put energy back into the grid," Wang said. The pilot program takes advantage of Con Edison's Smart Usage Program, which features some customers getting paid to lower their power usage during times of high demand. Con Ed shared in a statement, "It includes a diverse marketplace that enables innovation" and that right now mostly large buildings take advantage. "For our battery program, this allows everyday New Yorkers, tenants, co-ops, multi-family folks to participate in that same program," Wang said. "You get compensated based upon how much load you can reduce over a certain period." This virtual power plan uses remote monitoring software. "All the batteries are remotely controlled and monitored," said Lynne Irvin, battery engineer at Standard Potential. Irvin says with a click of button the batteries respond to Con Ed's needs, including charging off peak and discharging during peak usage. "Con Ed sends a call, a text, an email and we're able to immediately change the batteries over to the correct mode," Irvin said. "I like the idea of being able to take some sort of load off the grid," Spiller said, adding so far she loves the fact that the compensation goes beyond dollars. "My electricity went out on a super-hot day in New York and I was able to keep working and stay cool." Participants in the Responsible Grid pilot program receive $100 for each battery air conditioning pairing with Standard Potential. Wang said he hopes to pair batteries with heat Pump units this winter. There is a waiting list to get involved.
Washington Post
6 days ago
- Business
- Washington Post
Prestige Consumer Healthcare: Fiscal Q1 Earnings Snapshot
TARRYTOWN, N.Y. — TARRYTOWN, N.Y. — Prestige Consumer Healthcare Inc. (PBH) on Thursday reported fiscal first-quarter earnings of $47.5 million. The Tarrytown, New York-based company said it had profit of 95 cents per share. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.01 per share.
Associated Press
03-08-2025
- Entertainment
- Associated Press
Tampa Florida based Krewe of Europa to appear in the Tarrytown NY Halloween Parade
America's Krewe, the Krewe of Europa to appear in the famous Tarrytown NY Halloween celebration 'The Krewe is excited to be part of the Tarrytown Halloween Parade, home of the Headless Horseman. We have participated in Halloween parades across the globe, and are excited to be part of this event '— Craig Bachler TAMPA , FL, UNITED STATES, August 3, 2025 / / -- The Krewe of Europa ®, a Tampa Florida USA based 501c3 social and philanthropy organization with members across the United States and Europe have announced their appearance in the 2025 Tarrytown NY Halloween Parade October 25th, 2025. 'The Krewe is the first and only International Krewe and has marched in parades across from Juneau Alaska to Pernik Bulgaria' according to Craig Bachler, President of the Board of Trustees. 'The Krewe is excited to be part of the Tarrytown Halloween Parade, home of the Headless Horseman on October 25th, 2025. We have participated in many Halloween parades across the globe, but are excited to be part of this community based parade in 'Sleepy Hollow according to Bachler. Our 2025 theme is Dead Pirates, Remembering the Brethan. The Age of Discovery, also known as the Age of Exploration and the Great Navigation's, a period in European history from the early 15th century to the early 19th century. This period in history has influenced the start of our nation. Europa has members representing all 44 European Countries in colorful costumes of each country. Europa was formed by a global group of professionals that wanted to bring the US Gulf Coast krewe life to the world's stage by following their motto of 'Making Miles of Smiles Across the Globe, One Parade at a Time' while celebrating history. Europa travels to major parades across the globe, and has appeared in an Independence Day parade in Alaska, in St Patrick's in Boston Ma, Galway City and Craughwell Ireland, America's Hometown Thanksgiving in Plymouth Ma celebrating the 400th anniversary of Thanksgiving, Blankenberg Belgium Halloween parade, Salem Mass Halloween parade and annually at the Gatlinburg Tn Fantasy of Lights and returning to Boston for the 2026 St Patrick's parade. 2025 has been a historic year as the Krewe paraded in Ireland for a St Patrick's parade, Tivat Montenegro for their International Carnival and soon to Sabac Serbia among all the major US based parades the Krewe has participated in to date. Since first forming, the Krewe has participated in over 30 parades in six countries with an estimated audience of over 10 million spectators. The Krewe has been featured across the US in numerous television interviews and many publications. Craig Bachler Krewe of Europa email us here Visit us on social media: LinkedIn Instagram Facebook YouTube Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Yahoo
01-08-2025
- Business
- Yahoo
Regeneron beats second-quarter results estimates on Dupixent sales boost
(Reuters) -Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand for its blockbuster eczema treatment, Dupixent, sending its shares up nearly 3% in premarket trading. Investors have set a high bar for Regeneron and French partner Sanofi's Dupixent, one of the U.S. drugmaker's growth drivers, especially after it received approval to treat a common lung condition called chronic obstructive pulmonary disease last year. Sales of the anti-inflammatory drug rose 22% to $4.34 billion, compared with an estimate of $4.14 billion. The Tarrytown, New York-based company is also banking its cancer treatment, Libtayo, to drive future growth at a time when its blockbuster eye disease drug Eylea has been grappling with stiff competition from cheaper versions and rival drugs such as Roche's Vabysmo. U.S. sales of Eylea, jointly developed with Bayer AG, fell 25% to $1.15 billion, including $393 million from the higher, 8-milligram dose version of the drug. Analysts were expecting $2.17 billion in total Eylea sales. Roche reported Vabysmo sales of 2.07 billion Swiss francs ($2.54 billion) last week, slightly below analyst expectations. On an adjusted basis, Regeneron earned a quarterly profit of $12.89 per share, compared with analysts' average expectation of $8.44 per share, according to data compiled by LSEG. The company's total revenue for the quarter was $3.68 billion, above an expectation of $3.28 billion. Skin cancer drug Libtayo brought in sales of $377 million, versus analysts' average estimate of $338.75 million. Separately, Regeneron is among 17 drugmakers that have received a letter from the U.S. President Donald Trump asking them to slash U.S. prescription drug prices to match overseas rates. ($1 = 0.8161 Swiss francs) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
01-08-2025
- Business
- Yahoo
Regeneron beats second-quarter results estimates on Dupixent sales boost
(Reuters) -Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand for its blockbuster eczema treatment, Dupixent, sending its shares up nearly 3% in premarket trading. Investors have set a high bar for Regeneron and French partner Sanofi's Dupixent, one of the U.S. drugmaker's growth drivers, especially after it received approval to treat a common lung condition called chronic obstructive pulmonary disease last year. Sales of the anti-inflammatory drug rose 22% to $4.34 billion, compared with an estimate of $4.14 billion. The Tarrytown, New York-based company is also banking its cancer treatment, Libtayo, to drive future growth at a time when its blockbuster eye disease drug Eylea has been grappling with stiff competition from cheaper versions and rival drugs such as Roche's Vabysmo. U.S. sales of Eylea, jointly developed with Bayer AG, fell 25% to $1.15 billion, including $393 million from the higher, 8-milligram dose version of the drug. Analysts were expecting $2.17 billion in total Eylea sales. Roche reported Vabysmo sales of 2.07 billion Swiss francs ($2.54 billion) last week, slightly below analyst expectations. On an adjusted basis, Regeneron earned a quarterly profit of $12.89 per share, compared with analysts' average expectation of $8.44 per share, according to data compiled by LSEG. The company's total revenue for the quarter was $3.68 billion, above an expectation of $3.28 billion. Skin cancer drug Libtayo brought in sales of $377 million, versus analysts' average estimate of $338.75 million. Separately, Regeneron is among 17 drugmakers that have received a letter from the U.S. President Donald Trump asking them to slash U.S. prescription drug prices to match overseas rates. ($1 = 0.8161 Swiss francs) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
